Supplementary Materials

Table S1. The antibodies used in this study

Antibodies	**Catalog#**	**Source**
anti-β-Actin	A5441	Millipore-Sigma
anti-t-ERK	#4695	Cell Signalling Technology
anti-p-ERK	#4370	Cell Signalling Technology
anti-t-AKT	#4691	Cell Signalling Technology
anti-p-AKT Ser473	#4060	Cell Signalling Technology
anti-p-AKT Thr308	#13038	Cell Signalling Technology
anti-t-HER3	#4754	Cell Signalling Technology
anti-p-HER3	#2842	Cell Signalling Technology
anti-p-AKT Thr308 (IHC)	BS4009	Bioworld Technology
anti-t-HER3 (IHC)	2220243	ZENBIO



Figure S1. BCPAP cells were treated with 0.5 μM DSF/Cu alone or in combination with 2 mM NAC for 48 h, followed by a 1.5-h incubation with an ROS-sensitive fluorescent dye DCF-DA. The ROS-positive cells were measured by flow cytometer (left panel), and the mean fluorescence intensity of three independent experiments was then calculated by Student's t test (right panel). Data presented as means ± SD. *** $P < 0.001$.



Figure S2. BCPAP cells were treated with DSF/Cu (500 nM: 500 nM) and PLX4032 (2 μM) , individually or in combination, for 48 h, and cell apoptosis was then measured by flow cytometry. Data presented as means ± SD. *** $P < 0.001$.



Figure S3. The percentage of Ki-67-positive cells was counted and compared among the indicated groups. Data presented as means ± SD. * $P < 0.05$; *** $P < 0.001$.